Oramed Pharmaceuticals (ORMP) Change in Accured Expenses (2016 - 2026)

Oramed Pharmaceuticals (ORMP) has 11 years of Change in Accured Expenses data on file, last reported at $149000.0 in Q1 2026.

• Quarterly Change in Accured Expenses rose 348.33% year-over-year to $149000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $149000.0 (down 96.39% YoY) and the FY2025 annual result came in at -$60000.0, down 101.7% from the prior year.
• Change in Accured Expenses improved to $149000.0 in Q1 2026, from -$60000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $3.5 million in Q4 2024 to a low of -$2.2 million in Q4 2023.
• A 5-year average of $139100.0 and a median of $1500.0 in 2022 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 221400.0% in 2024, down 13420.0% in 2024.
• Tracing ORMP's Change in Accured Expenses over 5 years: stood at $2000.0 in 2022, then tumbled by 111650.0% to -$2.2 million in 2023, then surged by 257.96% to $3.5 million in 2024, then tumbled by 101.7% to -$60000.0 in 2025, then jumped by 348.33% to $149000.0 in 2026.
• The last three Change in Accured Expenses figures came in at $149000.0 (Q1 2026), -$60000.0 (Q1 2025), and $3.5 million (Q4 2024), per Business Quant data.